Ark Therapeutics Says Data Positive On Trinam For Kidney Dialysis

LONDON (AFX) - Ark Therapeutics Group PLC announced positive results from a Phase II trial of its Trinam gene therapy for kidney failure patients.

MORE ON THIS TOPIC